[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why",
    "summary": "Eli Lilly (LLY) closed at $852.35 in the latest trading session, marking a -1.45% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=40a57910db8a84200a44ed9797b5ea0a3fcc621edae9a430904380830726040a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742939115,
      "headline": "Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why",
      "id": 133444835,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) closed at $852.35 in the latest trading session, marking a -1.45% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=40a57910db8a84200a44ed9797b5ea0a3fcc621edae9a430904380830726040a"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Lone Pine Capital Portfolio - Q4 2024 Update",
    "summary": "Lone Pine Capital's 13F portfolio value increased slightly from $13.41B to $13.47B. Check out the new stakes and significant stake additions to the portfolio.",
    "url": "https://finnhub.io/api/news?id=7b599a8cc87451e8f3c15fbf0e8c8056afc2603d09bb2b497796a664af570470",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742936366,
      "headline": "Tracking Lone Pine Capital Portfolio - Q4 2024 Update",
      "id": 133428778,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1143979227/image_1143979227.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Lone Pine Capital's 13F portfolio value increased slightly from $13.41B to $13.47B. Check out the new stakes and significant stake additions to the portfolio.",
      "url": "https://finnhub.io/api/news?id=7b599a8cc87451e8f3c15fbf0e8c8056afc2603d09bb2b497796a664af570470"
    }
  },
  {
    "ts": null,
    "headline": "Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30 in Chicago.",
    "url": "https://finnhub.io/api/news?id=473a20ed9eac2cfccf2e015b3a676bd938b51b6f9bc4501699cbc45ef9cda43b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742934900,
      "headline": "Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting",
      "id": 133444836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30 in Chicago.",
      "url": "https://finnhub.io/api/news?id=473a20ed9eac2cfccf2e015b3a676bd938b51b6f9bc4501699cbc45ef9cda43b"
    }
  },
  {
    "ts": null,
    "headline": "GLP-1s are driving returns on R&D investments for Big Pharma, report says",
    "summary": "Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular diabetes drug Ozempic.",
    "url": "https://finnhub.io/api/news?id=886287b88e14d44d8f090a00ca58279cf999ba6245f33e182435699cad6640f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742927160,
      "headline": "GLP-1s are driving returns on R&D investments for Big Pharma, report says",
      "id": 133444837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular diabetes drug Ozempic.",
      "url": "https://finnhub.io/api/news?id=886287b88e14d44d8f090a00ca58279cf999ba6245f33e182435699cad6640f8"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%",
    "summary": "NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.",
    "url": "https://finnhub.io/api/news?id=c54bc4c90accbd722a99816e3d4e7a4fc9f5074e0f7a61496455cf89a9d3b579",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742918640,
      "headline": "Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%",
      "id": 133444838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.",
      "url": "https://finnhub.io/api/news?id=c54bc4c90accbd722a99816e3d4e7a4fc9f5074e0f7a61496455cf89a9d3b579"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shot",
    "summary": "Novo Nordisk is making plans for a Wegovy successor amid uncertainty surrounding CagriSema.",
    "url": "https://finnhub.io/api/news?id=79340303734b44745e7e33aef684622dc72ae572e767606d47da50d287ff8b37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742918508,
      "headline": "Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shot",
      "id": 133444839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk is making plans for a Wegovy successor amid uncertainty surrounding CagriSema.",
      "url": "https://finnhub.io/api/news?id=79340303734b44745e7e33aef684622dc72ae572e767606d47da50d287ff8b37"
    }
  },
  {
    "ts": null,
    "headline": "Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company",
    "summary": "SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025. With the closing, Organovo receives an upfront payment, with futur",
    "url": "https://finnhub.io/api/news?id=5ed05a43c7de10ebb2c738d0a0f12b3f90300116e9e22292e78ce6b5de49f82e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742916300,
      "headline": "Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company",
      "id": 133444840,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025. With the closing, Organovo receives an upfront payment, with futur",
      "url": "https://finnhub.io/api/news?id=5ed05a43c7de10ebb2c738d0a0f12b3f90300116e9e22292e78ce6b5de49f82e"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (NYSE:LLY) The Best Stocks to Buy Now For the Long Term?",
    "summary": "We recently published a list of 10 Best Stocks to Buy Now For the Long Term. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to buy now for the long term. What’s Next for the Equity Markets? The US equity markets […]",
    "url": "https://finnhub.io/api/news?id=6e8bd1d1b62e03f0e1a9eb5f6dc853d5255c3932f45016a139703e1bafd266ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742910239,
      "headline": "Is Eli Lilly and Company (NYSE:LLY) The Best Stocks to Buy Now For the Long Term?",
      "id": 133375584,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Stocks to Buy Now For the Long Term. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to buy now for the long term. What’s Next for the Equity Markets? The US equity markets […]",
      "url": "https://finnhub.io/api/news?id=6e8bd1d1b62e03f0e1a9eb5f6dc853d5255c3932f45016a139703e1bafd266ee"
    }
  },
  {
    "ts": null,
    "headline": "Trump tariffs drive pharma manufacturing to US but risk inflation and disruption",
    "summary": "Pressure may grow on companies to repatriate production, raising production costs and potentially medicine prices too.",
    "url": "https://finnhub.io/api/news?id=5765941ca9210f9b96735c2a938c56302f7f3449ba1628457c22c1d86bcdda4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742904197,
      "headline": "Trump tariffs drive pharma manufacturing to US but risk inflation and disruption",
      "id": 133375585,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pressure may grow on companies to repatriate production, raising production costs and potentially medicine prices too.",
      "url": "https://finnhub.io/api/news?id=5765941ca9210f9b96735c2a938c56302f7f3449ba1628457c22c1d86bcdda4b"
    }
  },
  {
    "ts": null,
    "headline": "Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts",
    "summary": "Verve received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. Read more about VERV stock here.",
    "url": "https://finnhub.io/api/news?id=4a4e0fad7ee64a4cfb33be3eff4d8f947b3c87dde44110e15f82bfa247edd11a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742887710,
      "headline": "Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts",
      "id": 133370115,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196965065/image_2196965065.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Verve received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. Read more about VERV stock here.",
      "url": "https://finnhub.io/api/news?id=4a4e0fad7ee64a4cfb33be3eff4d8f947b3c87dde44110e15f82bfa247edd11a"
    }
  },
  {
    "ts": null,
    "headline": "Trump Tariff Uncertainty Will Break This Stock Market Calm, Brace for Another Storm. And 5 Other Things to Know Today.",
    "summary": "Trump Tariff Uncertainty Will Break This Stock Market Calm, Brace for Another Storm. And 5 Other Things to Know Today.",
    "url": "https://finnhub.io/api/news?id=1b79a994a2f0e264778ce8249c13bdfd5b7126323df55985dd4c80993c2e7d85",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742885760,
      "headline": "Trump Tariff Uncertainty Will Break This Stock Market Calm, Brace for Another Storm. And 5 Other Things to Know Today.",
      "id": 133376422,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Trump Tariff Uncertainty Will Break This Stock Market Calm, Brace for Another Storm. And 5 Other Things to Know Today.",
      "url": "https://finnhub.io/api/news?id=1b79a994a2f0e264778ce8249c13bdfd5b7126323df55985dd4c80993c2e7d85"
    }
  },
  {
    "ts": null,
    "headline": "GLP-1s boost pharma R&D projected return on investment: Deloitte",
    "summary": "Companies looking to compete in the GLP-1 market are adding value to the R&D spend across the pharma sector.",
    "url": "https://finnhub.io/api/news?id=8adb0a519bc25dd494f5bcd6fc0b384cd8459411a521b30b3433ae71c7024ad5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742875241,
      "headline": "GLP-1s boost pharma R&D projected return on investment: Deloitte",
      "id": 133367585,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies looking to compete in the GLP-1 market are adding value to the R&D spend across the pharma sector.",
      "url": "https://finnhub.io/api/news?id=8adb0a519bc25dd494f5bcd6fc0b384cd8459411a521b30b3433ae71c7024ad5"
    }
  },
  {
    "ts": null,
    "headline": "GLP-1s boosts pharma R&D projected return on investment: Deloitte",
    "summary": "Companies looking to compete in the GLP-1 market are adding value to the R&D spend across the pharma sector.",
    "url": "https://finnhub.io/api/news?id=846e93beccf8749989fa036b89e3f18ab0441710d5c9ae0274d16c05f0595593",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742875241,
      "headline": "GLP-1s boosts pharma R&D projected return on investment: Deloitte",
      "id": 133360340,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies looking to compete in the GLP-1 market are adding value to the R&D spend across the pharma sector.",
      "url": "https://finnhub.io/api/news?id=846e93beccf8749989fa036b89e3f18ab0441710d5c9ae0274d16c05f0595593"
    }
  }
]